Warp Sciences Raises $215M Series A for US Chemistry Labs

Warp Sciences is building a chemistry contractor whose laboratories also serve its AI development ambitions. The South San Francisco team wants to connect the work of producing research compounds with the evidence needed to improve laboratory automation, putting scientific services and model development inside the same operating business.

The company emerged from stealth on October 22, 2026 with $215M in funding. Lightspeed, which led the Series A, was joined by investors including Premji Invest, Mayfield, IVP, Lux Capital and Menlo Ventures. For biotech and pharmaceutical customers, the proposition is a domestic source of chemistry that becomes more capable as its people, equipment and software learn to work together.

A $215M Series A for physical research capacity

Warp's financing backs a business with obligations beyond shipping software. A chemistry contractor needs people who can make difficult molecules, instruments that produce dependable results and a working relationship with the scientists deciding what to try. The company's plan brings AI and robotics into those operations progressively, while experienced chemists lead the work.

The company's launch announcement describes a US-based chemistry contract research organization, or CRO. It identifies lead-optimization analog synthesis as the initial service: producing variations of molecules so research teams can compare them while pursuing a drug candidate. Customers determine which molecules to pursue and retain control of their programs; Warp has no proprietary drug pipeline.

Bloomberg reported an $865M post-money valuation, attributing that figure to the company. The financing therefore puts a substantial valuation behind an early chemistry business. Warp is financing chemistry facilities, automation and the organization needed to connect physical experiments to AI development.

Delivered compounds change the supplier's assignment

Warp's customer service page makes the commercial arrangement unusually explicit. The company charges per compound delivered, with pricing set in consultation with the customer. If Warp cannot produce a compound, the customer does not pay for it. That differs from buying capacity through full-time-equivalent staffing, a model Warp identifies as common in chemistry outsourcing.

For a research buyer, this moves part of the purchasing decision toward a tangible output. For Warp, it makes dependable synthesis relevant to the economics of each assignment. Skilled labor, equipment time and materials can still be consumed by an unsuccessful attempt, even when no compound is delivered. The advertised payment rule gives improvements in production reliability a direct commercial purpose.

The initial scope is specific: preclinical small-molecule programs, from milligram to multi-gram scale, typically involving elaborated molecules with 5-15 synthetic steps. Those details matter because the work involves sequences of decisions and operations, with opportunities for an earlier step to change what happens later. Automating an isolated action and delivering the requested compound are different engineering assignments.

Warp positions its service as domestic collaboration at offshore pricing. That is the company's stated offer; the inspected pages do not provide comparative cost or turnaround results. Customers considering the service would still need program-specific terms, quality requirements and delivery expectations. The company's current design-partner relationships give those conversations a place in how the service develops.

Four founders span chemistry, AI and operations

The current leadership team includes CEO Kevin Weil, CSO Sol Reisberg, COO DJ Patil and CTO Manohar Paluri. All 4 are co-founders. The team is based in South San Francisco, bringing the people responsible for chemistry, models and business operations into a shared laboratory-building effort.

Weil previously led product and science work at OpenAI. Paluri's background includes Meta and Facebook AI Research; Reisberg brings medicinal chemistry experience, including Terremoto Biosciences. Patil previously served as the first US Chief Data Scientist and helped build Devoted Health. These backgrounds are described in the launch materials and corroborated by participating investors, including Premji Invest.

Reisberg's experience buying outsourced chemistry gives the founding team a particular view of the customer relationship. In the company announcement, he describes the attraction of overseas providers' speed and value alongside concern about protecting program intellectual property. Warp is attempting to bring those buying priorities into a US service, where the customer can work directly with the chemists doing the assignment.

The staffing plan reflects the coordination required. Warp's careers page listed 8 openings when checked on October 23, spanning chemistry, robotics, software and AI. That is a hiring snapshot, rather than a statement of total headcount. It shows the range of work needed to connect the laboratory's practical routines with the systems intended to automate them.

Experimental evidence becomes part of the infrastructure

The founders' published manifesto sets out the longer ambition: record experimental outcomes, including failures, and use that evidence to improve AI models and laboratory capability. Alongside customer work, Warp plans dedicated experimental campaigns to generate data for its models. More automation is intended to expand the amount of experimentation, while better evidence helps guide subsequent work.

There are several jobs inside that plan. An experiment needs to be executed reliably, its conditions and outcome recorded usefully, and the resulting information connected to a decision about a future experiment. A lab can produce a great deal of information without automatically producing a better model. The usefulness of the record depends on what it allows the next scientist or system to understand.

Warp's company materials leave customer drug-program control with the customer. They do not disclose detailed contractual rules governing the reuse of customer experimental data, so the model-development ambition should not be read as a blanket claim to customers' research. Its dedicated experimental campaigns are a separately stated part of the data-generation plan.

For now, Warp says it is working with a small number of design partners whose chemists collaborate with its team week by week. Those relationships connect a large financing and a long scientific ambition to a repeated, specific assignment: agree on the compounds, do the chemistry and return material that lets a research program continue. The next round of experimental decisions will arrive through that working relationship.